BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 9, 2025
Breaking News: 100 days of uncertaintyBreaking News: 100 days of uncertaintyBreaking News: 100 days of uncertainty
  • Dollar sign between hands

    Sounds of relief as Masimo unloads audio division

    News of the sale of Masimo Corp.’s consumer audio unit may be music to the ears of investors, even at the steep discount from its original purchase price. Samsung Electronics Co. Ltd.’s Harman International Industries Inc. unit snapped up the Sound United business for about $350 million – roughly one-third of the $1.025 billion Masimo paid for the company in 2022.
  • Precision Neuro leads BCI race following FDA clearance

    The recent 510(k) clearance by the U.S. FDA for a core part of Precision Neuroscience Corp. brain-computer interface technology is certainly a boon for the company, and others developing the devices. For the millions of people suffering from health disorders, such as motor neuron disease, spinal cord injury or severe stroke, its sign that a solution which could transform their lives could be just a few years away.
  • Sounds of relief as Masimo unloads audio division

    News of the sale of Masimo Corp.’s consumer audio unit may be music to the ears of investors, even at the steep discount from its original purchase price. Samsung Electronics Co. Ltd.’s Harman International Industries Inc. unit snapped up the Sound United business for about $350 million – roughly one-third of the $1.025 billion Masimo paid for the company in 2022.
  • Precision Neuro leads BCI race following FDA clearance

    The recent 510(k) clearance by the U.S. FDA for a core part of Precision Neuroscience Corp. brain-computer interface technology is certainly a boon for the company, and others developing the devices. For the millions of people suffering from health disorders, such as motor neuron disease, spinal cord injury or severe stroke, its sign that a solution which could transform their lives could be just a few years away.
  • FDA posts regulation for 2018 test for hematological malignancies

    The U.S. FDA in 2018 granted the de novo petition by Seattle-based Adaptive Biotechnologies Corp. for the company’s DNA test for evaluation of residual hematological malignancies, but waited until March 8, 2025, to post notice of the attendant regulation.
  • Oncosil’s brachytherapy device outperforms SBRT in pancreatic cancer

    Oncosil Medical Ltd.’s brachytherapy device outperformed stereotactic body radiation therapy plus chemotherapy in patients with unresectable or borderline-resectable locally advanced pancreatic cancer, according to a comparative analysis.
  • M&A activity dominates Q1, nearly 99% total med-tech deal value

    In the first quarter of 2025, the med-tech sector saw a total of $149.08 million raised through 475 deals. This marked a significant decline from the $519.14 million raised in Q4 2024, representing the smallest quarterly total recorded by BioWorld MedTech since 2018.
  • Today's news in brief

    BioWorld MedTech briefs for May 8, 2025.

BioWorld Insider Podcast

Play buttonRobert Williamson, CEO of Triumvira Immunologics, and Hernan Bazan, CEO of South Rampart Pharma, discuss bracing for tariffs, NIH grant cuts and gifting China a biopharma leadership position.
Listen now

Digital health

  • Handshake with digital globe overlay

    Med-tech financings and guidance strong despite tariffs

    Deals and M&A
    April data and first quarter earnings reports show remarkable resilience in med tech, even as other sectors continue to suffer in response to tariffs and changing regulations. Not that tariffs proved insignificant: several companies reported annualized impacts north of half a billion dollars, but...
  • voinosis

    Voinosis uses AI and voice analytics for early dementia diagnosis

    Neurology/psychiatric
    Seoul, South Korea-based Voinosis Co. Ltd. filed for potential worldwide protection of its AI-based system that allows for the early detection cognitive impairment, dementia, Alzheimer’s disease and hearing loss through voice analysis.
  • Gears with regulatory words

    Advamed AI policy document criticizes FDA’s AI PCCP guidance

    Regulatory
    The Advanced Medical Technology Association released a policy proposal for AI in medical devices that took the U.S, FDA to task for its guidance for predetermined change control protocols for AI, stating that the guidance is “inconsistent with the statutory authority” for PCCPs.
  • Illustration of human body composed of molecules

    Device makers wary of FDA guidance for AI-enabled software functions

    Medical devices and technologies
    The U.S. FDA’s January 2025 draft guidance for AI-enabled device software functions has not fared well in terms of industry response. Two major trade associations argue that the draft is at least somewhat redundant with existing agency guidance.
More in Digital health

Today's news in brief

  • Appointments and advancements for May 8, 2025

  • Financings for May 8, 2025

  • In the clinic for May 8, 2025

  • Other news to note for May 8, 2025

  • Regulatory actions for May 6, 2025

Regulatory

  • Congress poised to revisit two legislative proposals for patents

  • US-funded gain-of-function research paused for stiffer oversight

  • UK’s NICE seeks to apply price pressures on drug-eluting stents

  • Q’apel’s withdrawal of Hippo ends patent lawsuit with Route 92

  • Annual US 301 trade report has louder bark

  • EO offers US onshoring relief, FDA steps up foreign inspections

  • US states seek to undo HHS reorg, terminations

  • Australia follows Canadian lead; Labor win a sharp rebuke to Trump

  • Annual US 301 trade report has louder bark

  • Compliance still important under new Department of Justice

Financings

  • Colon cancer illustration

    Safeheal secures €35M for endoluminal fecal bypass system

    Gastrointestinal
    Safeheal SAS raised €35 million (US$39.72 million) in an oversubscribed series C financing round for its temporary endoluminal fecal bypass system, Colovac, which is placed in the colon following colorectal resection. The funds will be used to complete an investigational device exemption pivotal...
  • Aktiia SA raises $42M for BP monitoring platform, rebrands to Hilo

    Cardiovascular
  • Year-over-year rise as med-tech financings surpass $10B in 2025

  • PULSAR gives Kardium legs in PFA horse race

    Cardiovascular
  • Deepull raises €50M for bloodstream infection test

    Infection
More in Financings

Newco news

  • Wearoptimo microwearable hydration sensor

    Wearoptimo’s hydration sensor outperforms gold standard tests

    Clinical
    Health care technology company Wearoptimo Ltd. developed a next-generation microwearable sensor that accurately detects hydration levels, outperforming the needle-based gold standard.
  • Patent filed for multiweek, multitarget CGM-like wearable sensor

    Cardiovascular
    Researchers from the University of Cincinnati filed for protection of an electrochemical aptamer-based biosensor technology with improved sensitivity and longevity, which has the potential for monitoring several biomarkers over sustained periods.
  • Updoc patents AI-powered diabetes management platform

    Diabetes
    The first patent from Palo Alto, Calif.-headquartered Updoc Inc. provides protection for their development of an artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient.
  • Trio of neuro disease-focused firms highlighted at KIMES 2025

    Cardiovascular
  • Researchers develop visual prosthetic to restore sight

    Neurology/psychiatric
  • New Zealand’s Avasa develops world-first arterial coupler

    Cardiovascular
  • Astellas-Yaskawa JV to build robot-based cell production platform

    Deals and M&A
More in Newco news

Deals and M&A

  • World globe, DNA sequencing illustration.

    Emerging markets presents opportunities for med tech

    Financings
    Med tech companies were reminded that there are opportunities in emerging and growing markets as they look for ways to adapt to the uncertainties created by the U.S. administration threats of import tariffs. With large populations, and relatively untapped markets, these opportunities represent...
  • Handshake, businessmen holding dollar sign, lightbulb

    Startup, strategic relationship dependent on fair terms

    Europe
    Partnership agreements between startups and strategics need to be based on terms that are fair otherwise they will be rejected.
  • US flag, gavel, book

    DOJ rolls out task force for review of burdensome regulation

    Regulatory
    The U.S. Department of Justice recently announced the formation of a task force that will advocate the roll-back of regulations that affect a wide swath of sectors of the American economy. Health care is one of the areas of interest for the task force, which will examine state as well as federal...
  • Cancer tumor in breast illustration

    Radnet doubles down on breast cancer with $103M Icad buy

    Cancer
    Radnet Inc. expanded its commitment to the use of AI in improving diagnosis of breast cancer with an all-stock purchase of Icad Inc. for approximately $103 million. The transaction is expected to close in the second or third quarter of 2025.
  • GE Healthcare

    GE Healthcare taps into Japan radiopharma market with Nihon buy

    Regulatory
    GE Healthcare Technologies Inc. gained full ownership of Nihon Medi-Physics Co. Ltd. after acquiring the remaining 50% stake from Sumitomo Chemical Co. Ltd. on March 31.
More in Deals and M&A

U.S.

  • Diabetes segment reports good news all around

  • Resmed prevails over Cleveland Medical in CPAP patent review

  • Cellecta profiles 19,000 genes from a drop of blood

  • CMS vows to put more emphasis on MA plans’ prior authorization

  • FDA clears Satsuma’s Atzumi for migraine

  • FDA’s Tarver says agency open to improvement of third-party reviews

  • Klobuchar reiterates opposition to Trump tariffs

  • Field Medical, Adagio look to VT for break out indication

  • SEC scores $17M win over investor fraud allegations

  • Senate hearing: US biomedical research at a crossroads

Europe

  • ViroCAP

    Viromed signs deals for cold plasma technology devices

    Dermatologic
    Viromed Medical AG recently signed a couple of deals to get its devices based on cold plasma technology into the hands of clinicians to treat patients with skin diseases and pneumological infections.
  • PFA continues to set EP hearts aflutter

    Clinical
  • Vivasure Perqseal vascular closure system lands CE mark

    Regulatory
  • HRA/ACC release same-day discharge guidance for cardiac ablation

    Clinical
  • Differences in risk classification schema not necessarily a bar on reliance

    Regulatory
More in Europe

Asia-Pacific

  • Conceptual image for brain cancer treatment

    FDA issues CRL for Telix's glioma imaging agent, wants more data

    Regulatory
    The U.S. FDA issued a complete response letter (CRL) to Telix Pharmaceuticals Ltd. for its NDA for glioma imaging agent, TLX-101-CDx (floretyrosine F18 or 18F-FET, Pixclara), citing the need for additional confirmatory clinical evidence.
  • Med tech majors unfazed by tariffs

    U.S.
    First quarter earnings reports from Edwards Lifesciences Corp., Intuitive Surgical Inc. and Boston Scientific Corp. support trends seen earlier: Larger med-tech companies expect substantial tariff hits, but also have confidence that they can absorb the impact with fairly minor adjustments.
  • Sky Labs seeks global expansion of world’s first BP monitor ring

    Clinical
    Sky Labs Inc. CEO and founder Jack Byunghwan Lee reported on plans to greatly expand the market for the company’s blood pressure monitor ring, including seeking regulatory approvals for the CART BP products in the U.S., Europe and Japan.
  • Telix’s brain cancer radiotherapy shows phase II survival benefit

    Clinical
  • AI-enhanced mammogram readings are better, but ignored

    Clinical
  • FDA gives nod to Orthocell’s 510(k) for nerve repair product

    Regulatory
  • Radiopharmaceuticals stake more territory in breast cancer care

    Clinical
More in Asia-Pacific

Clinical

  • J&J reports completion of first cases with Ottava robotic system

    Regulatory
    Johnson & Johnson’s Medtech division reported the completion of the first cases in the clinical trial for the Ottava robotic surgical system. The cases mark the first clinical experience with the Ottava system, which has been a long time in...
  • Saliva test predicts prostate cancer better than PSA

    Cancer
    U.K. scientists developed a saliva-based test which better predicts the risk of prostate cancer than current prostate-specific antigen (PSA) blood tests by analyzing DNA to look for genetic variants linked to prostate cancer and calculating a...
  • PFA non-inferior, even superior, to cryoablation for paroxysmal AF

    Cardiovascular
    Pulsed field ablation using Boston Scientific Corp.’s Farapulse system was non-inferior and even superior, slightly, to Medtronic plc’s Artic Front Advance cardiac cryoablation system in treating patients with paroxysmal atrial fibrillation.
  • Radiopharmaceuticals stake more territory in breast cancer care

    Cancer
    Radiopharmaceuticals, including 16α-18F-fluoro-17β-estradiol (18F-FES) PET/CT, are emerging as powerful tools with new diagnostic and therapeutic potential in breast cancer diagnosis and treatment, Han Sang-won, professor from the department of...
  • AI used to ID abnormalities in unborn babies

    Neonatal/pediatrics
    The use of an AI tool could speed up the time it takes to do pregnancy scans by almost half and it is still able to identify any abnormalities in the fetus, researchers found. Results from a study showed the AI tool used to assist with 20-week...
  • Acrivon narrows focus for ACR-368 in endometrial cancer

    Cancer
    Acrivon Therapeutics Inc. provided updated phase II data for checkpoint kinase candidate ACR-368, highlighting promising response rates for biomarker-positive patients with endometrial cancer and raising the possibility of an accelerated pathway...
More in Clinical

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple backgroundBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.


Recent episodes:

  • Two CEOs discuss bracing for tariffs, NIH grant cuts and
    gifting China biopharma leadership position
  • As biopharma investments stumble, med tech surges
  • Mega money well spent? Mammoth mergers fall short of the dream
  • Healing the health divide for women
  • Modifi gets creative on the rocky road to a multibillion-dollar buyout
  • A quantum leap into the future of drug development
  • Gene and cell therapies will propel innovation, says Astellas CCO
  • Capricor’s CEO pursues a BLA and talks rare disease
  • The first half of 2024 was strong as M&As and financings dominate
  • The cost of delays in development and sales: It’s probably not what you think

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing